Microdosing GLP-1:
Not Just for Weight Loss

What microdosing GLP-1 actually means

Standard GLP-1 weight-loss protocols typically start at 0.25mg semaglutide weekly and titrate up to 2.4mg (Wegovy dosing). Microdosing intentionally stays at or below the starting dose — 0.25mg to 0.5mg weekly — to access the metabolic and systemic benefits of GLP-1 receptor activation without driving significant caloric deficit or weight loss.

GLP-1 receptors are found throughout the body — not just in the gut and pancreas. They're expressed in the brain, heart, kidneys, immune cells, and adipose tissue. The systemic effects of GLP-1 activation at low doses include reduced neuroinflammation, improved insulin sensitivity, lower circulating inflammatory markers (CRP, IL-6), and potentially cardioprotective effects — independent of weight loss.

This is why people who are already lean — athletes, biohackers, health optimizers — are interested in the protocol. The weight loss is incidental or minimal. The metabolic optimization is the point.

The muscle preservation advantage

Standard GLP-1 weight-loss protocols have a well-documented downside: muscle loss. In clinical trials, approximately 25–40% of weight lost on semaglutide and tirzepatide is lean mass. For athletes and people who train seriously, this is unacceptable.

Microdosing addresses this in two ways. First, the lower caloric restriction means the body isn't in the aggressive deficit that triggers muscle catabolism. Second, GLP-1 receptor activation has direct effects on muscle metabolism — improved insulin sensitivity means nutrients partition more efficiently into muscle tissue rather than fat.

Combined with adequate protein intake (1g+ per lb of bodyweight) and progressive resistance training, the microdose protocol is used by athletes for body recomposition: losing fat while maintaining or building muscle simultaneously. This is physiologically difficult without pharmacological support — GLP-1 makes it significantly more achievable.

The longevity angle

The longevity research on GLP-1 is early but compelling. In animal models, GLP-1 receptor agonists have extended lifespan and healthspan through multiple mechanisms: reduced oxidative stress, improved mitochondrial function, neuroprotection, and cardiovascular protection.

In humans, the LEADER trial (liraglutide) and SELECT trial (semaglutide) showed significant cardiovascular mortality reductions — effects that appear partially independent of weight loss. The SELECT trial is particularly notable: cardiovascular event reductions appeared before significant weight loss, suggesting direct cardioprotective mechanisms.

Reducing visceral fat, improving metabolic flexibility, and lowering chronic inflammation are among the most well-validated longevity interventions available. Microdose GLP-1 targets all three.

The Marrow performance protocol

Marrow's performance protocol combines microdose compounded semaglutide with physician oversight, an AI health coach that understands your training and nutrition context, and optional stack additions (NAD+, Sermorelin) for a comprehensive longevity approach.

What the critics say (and why it still makes sense)

The honest caveat: rigorous randomized controlled trials specifically on GLP-1 microdosing in healthy, lean individuals do not yet exist. The protocol is extrapolated from standard-dose trial data, mechanistic research, and physician clinical experience.

Critics, including some researchers, have noted that the longevity benefits are unproven at microdose levels in healthy populations. This is fair. The protocol is not a magic bullet.

That said: the safety profile of GLP-1 agonists at low doses is well-established from diabetes and obesity trials. The known mechanisms (metabolic improvement, inflammation reduction, insulin sensitization) are relevant regardless of weight status. And the cost-benefit calculation for a physician-supervised trial is favorable for most health-motivated adults.

Marrow's position: we present this as what it is — a physician-supervised optimization protocol with emerging evidence, not a cure or a replacement for fundamentals (training, nutrition, sleep). We won't overpromise.